Payment overview · 2025
General Payments
$1,404.88
85 reported records · 18 companies
Healthcare provider profile · identity verified
Nicholas T Pecorelli, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WOOD-RIDGE, NJ · NPI 1699744755
Verified facts
What the public records show
CMS Open Payments records show Nicholas T Pecorelli, M.D. received $1,404.88 in general payments during 2025 across 85 reported records.
Novo Nordisk Inc accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $401.42 | 28.6% | 23 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $158.24 | 11.3% | 10 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $141.05 | 10.0% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.75 | 6.3% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.52 | 5.7% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.63 | 5.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.27 | 4.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.52 | 3.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.04 | 3.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $49.09 | 3.5% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.67 | 3.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.76 | 3.4% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.84 | 2.6% | 3 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $33.38 | 2.4% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.93 | 1.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.71 | 1.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.69 | 1.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.37 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,404.88 | 85 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $323.34 | 18 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $158.24 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $158.24 | 10 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $141.05 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $115.94 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.03 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $54.00 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.33 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $51.04 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.03 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $49.09 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $48.67 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.65 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.84 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.74 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.26 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $33.38 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $33.38 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.53 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 141 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 149 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 151 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 39 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 41 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
141 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
141 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1172 | 333 |
| Atorvastatin Calcium | Atorvastatin Calcium | 823 | 225 |
| Amlodipine Besylate | Amlodipine Besylate | 642 | 188 |
| Alprazolam | Alprazolam | 626 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 581 | 142 |
| Metoprolol Succinate | Metoprolol Succinate | 511 | 133 |
| Losartan Potassium | Losartan Potassium | 495 | 131 |
| Lisinopril | Lisinopril | 387 | 106 |
| Metformin Hcl | Metformin Hcl | 386 | 107 |
| Furosemide | Furosemide | 317 | 119 |
| Allopurinol | Allopurinol | 314 | 83 |
| Omeprazole | Omeprazole | 232 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 74 |
| Escitalopram Oxalate | Escitalopram Oxalate | 225 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 210 | 62 |
| Azithromycin | Azithromycin | 207 | 181 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 61 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 201 | 56 |
| Glimepiride | Glimepiride | 186 | 57 |
| Ramipril | Ramipril | 181 | 54 |
| Simvastatin | Simvastatin | 178 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 51 |
| Ezetimibe | Ezetimibe | 167 | 55 |
| Metformin Hcl Er | Metformin Hcl | 167 | 53 |
| Ozempic | Semaglutide | 151 | 28 |
| Jardiance | Empagliflozin | 149 | 41 |
| Eliquis | Apixaban | 141 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 119 | 38 |
| Nebivolol Hcl | Nebivolol Hcl | 118 | 34 |
| Carvedilol | Carvedilol | 116 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 88 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 25 |
| Finasteride | Finasteride | 87 | 30 |
| Gabapentin | Gabapentin | 87 | 26 |
| Lorazepam | Lorazepam | 87 | 11 |
| Famotidine | Famotidine | 82 | 29 |
| Xarelto | Rivaroxaban | 82 | 17 |
| Sertraline Hcl | Sertraline Hcl | 77 | 16 |
| Januvia | Sitagliptin Phosphate | 74 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 72 | 24 |
| Meloxicam | Meloxicam | 72 | 22 |
| Alendronate Sodium | Alendronate Sodium | 67 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 33 |
| Valsartan | Valsartan | 64 | 14 |
| Diazepam | Diazepam | 62 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 61 | 19 |
| Methylprednisolone | Methylprednisolone | 60 | 52 |
| Tramadol Hcl | Tramadol Hcl | 60 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 58 | 33 |
| Fenofibrate | Fenofibrate | 57 | 16 |
| Montelukast Sodium | Montelukast Sodium | 57 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 16 |
| Atenolol | Atenolol | 54 | 15 |
| Warfarin Sodium | Warfarin Sodium | 54 | 11 |
| Synthroid | Levothyroxine Sodium | 52 | 16 |
| Naproxen | Naproxen | 47 | 29 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 46 | 15 |
| Spironolactone | Spironolactone | 43 | 13 |
| Cephalexin | Cephalexin | 41 | 32 |
| Farxiga | Dapagliflozin Propanediol | 41 | 14 |
| Nifedipine Er | Nifedipine | 41 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 39 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 12 |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | 11 |
| Valacyclovir | Valacyclovir Hcl | 32 | 13 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 13 |
| Telmisartan | Telmisartan | 30 | suppressed |
| Colchicine | Colchicine | 29 | 12 |
| Estradiol | Estradiol | 29 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Nadolol | Nadolol | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | 16 |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 21 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 12 |
| Prednisone | Prednisone | 17 | 12 |
| Digoxin | Digoxin | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 11 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Cefadroxil | Cefadroxil | 14 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 13 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ativan | Lorazepam | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,404.88 · 85 records | Novo Nordisk Inc | Cologuard Collection Kit, ELIQUIS, FARXIGA, FASENRA, FREESTYLE LIBRE, Fluad, Flucelvax, JARDIANCE, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, PAXLOVID, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error